Neural Noise

Nudge: non-invasive BCI startup (Fred Ehrsam)

2 min read

  • Coinbase co-founder Fred Ehrsam entered the neurotech space with non-invasive BCI startup Nudge (The Debrief, May 2025).1
  • Nudge was reported in press only as of May 2025, with no device or trial details yet; it signals capital and high-profile talent moving into consumer/clinical BCI.1 1

Weekly enrichment (2026-07-20)

  • Nudge was founded in 2024 in San Francisco by Fred Ehrsam (CEO, Coinbase and Paradigm co-founder), Jeremy Barenholtz (President & CTO, previously VP of Product & Technology at Neuralink), and Quintin Frerichs.23
  • Unlike implant-based competitors (Neuralink, Synchron, Precision Neuroscience, Blackrock Neurotech, Paradromics), Nudge takes a non-invasive approach using low-intensity focused ultrasound (LIFU) delivered from outside the skull, with nothing implanted and no craniotomy.34
  • In April 2025 Nudge unveiled its first product, Nudge Zero: a helmet-like, MRI-compatible, multi-emitter ultrasound phased array that converges sound waves on a predetermined deep-brain target; an initial version was reportedly built in about six months.34
  • Nudge reports using structural MRI to plan targeting and an MR-based acoustic radiation force imaging method to visualize where ultrasound energy actually lands, supporting per-patient targeting across sessions; Nudge Zero is intended for hospitals and research centers rather than home use.3
  • The company raised a $100 million Series A led by Thrive and Greenoaks, and by mid-2025 had hired at least eight former Neuralink employees; LinkedIn data indicates roughly 32 employees.234
  • Initial clinical focus is on high-unmet-need, partially treatment-resistant conditions: anxiety, chronic pain, addiction, plus OCD and depression, targeting circuits such as limbic/prefrontal (anxiety), nucleus accumbens (addiction), and thalamic/cingulo-frontal systems (pain).3
  • The stated long-term “north star” is a miniaturized, headphone-like consumer device for cognitive enhancement and mental well-being; in April 2025 Nudge described four workstreams (shrinking drive electronics, advanced transducer fabrication, embedded imaging/localization, and per-user personalization), with no consumer product name yet announced.34
  • LIFU addresses the depth-focality trade-off of surface tools like TMS while avoiding the surgery of deep brain stimulation, though the evidence base is still limited to animal studies and small human feasibility trials, with larger controlled studies on dosing, durability and safety still needed.3
  • The broader market context: global neurotechnology spend is projected to grow from about $15.3 billion (2024) to roughly $52.9 billion by 2034, with MRI-guided focused-ultrasound devices a smaller adjacent segment (about $223.5 million in 2024).3

Footnotes

  1. https://news.google.com/rss/articles/CBMi4AFBVV95cUxPRnVTTUhWR3ZDRmI2ekNMLUNROUZ1NEEtYmdmbVZremVVZ1ZyYjBNY19na2MwZnpkUzFiWjRQYmtEMmtEa1BJLWNYa09YTUZVSVAwMll4V1V0R1VpbXJ6X3puQlA2akxkS25Xb3VHM1pkenUzbThQeERxSUJFdy1zeHo3eS1nMzJJZmRhaWFTWndlX2Q2clRSMURERjZQUGtiUC0yUlRLZDZJOFBMZmxzUnFod0hsamhjNE84c0Y4dXZQeE9ZM0NfVW00LVluT3hTUTc5TWEtaEl6bTltOUFvOA?oc=5 ↩ ↩2 ↩3

  2. https://www.forbes.com/sites/robtoews/2025/12/07/the-next-frontier-for-ai-is-the-human-brain/ ↩ ↩2

  3. https://research.contrary.com/company/nudge ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  4. https://thedebrief.org/from-blockchain-to-brainwaves-coinbase-co-founder-fred-ehrsam-enters-the-neurotech-race-with-non-invasive-bci-startup-nudge/ ↩ ↩2 ↩3 ↩4

Graph View